Cardima dispute headed to panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's Medical Device Dispute Resolution Panel will convene April 19 in Gaithersburg, Md., to hear Cardima's arguments for PMA approval of its Revelation Tx atrial fibrillation device. An advisory panel voted unanimously to reject the application in 2003, citing study design problems (1"The Gray Sheet" June 2, 2003, p. 3). A dispute is eligible for review by the panel only if the matter is based on "sound scientific grounds," and if "sufficient effort" has been made to resolve the complaint through less formal mechanisms...
You may also be interested in...
Cardima’s Revelation: AF Self-Monitoring, Hazy Endpoints Hamper Review
The ability of self-reporting to accurately track reduction in atrial fibrillation burden is cast into doubt by FDA panel experience with Cardima's Revelation ablation system data submission
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.